Joann P. Palma

TL;DR: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.

TL;DR: It is found that the nitroso metabolite of iniparib forms adducts with many cysteine-containing proteins in tumor cells, and the primary mechanism of action for inipirib is likely not via inhibition of PARP activity.

TL;DR: Robust ABT-888+TMZ efficacy is observed across a spectrum of tumor types, including orthotopic and metastatic implantation, and this novel combination may broaden the clinical use of TMZ beyond melanoma and glioma.

TL;DR: It is suggested that cancer cells upregulate the homologous recombination DNA repair pathway to compensate for the loss of base excision repair, which may account for the observed resistance to treatment with TMZ and ABT-888.

TL;DR: ABBV-399 represents a novel therapeutic strategy to deliver a potent cytotoxin to c-Met–overexpressing tumor cells enabling cell killing regardless of reliance on MET signaling and has progressed to a phase I study where it has been well tolerated and has produced objective responses.